Nektar Therapeutics Q1 net loss narrows on lower G&A costs

Nektar Therapeutics

07/05/2026 21:31

Overview

US biotech firm's Q1 revenue rose slightly yr/yr, net loss narrowed

Operating expenses fell due to lower G&A costs, offset by higher R&D spending

Outlook

Company expects to initiate Phase 3 rezpegaldesleukin trial in atopic dermatitis by July 2026

End-of-Phase 2 FDA meeting for alopecia areata program expected in Q2 2026

Company says it is well positioned to advance rezpegaldesleukin into late-stage development

Result Drivers

R&D SPENDING - Higher R&D costs driven by increased expenses for rezpegaldesleukin development as Phase 3 program preparation began

LOWER G&A COSTS - G&A expenses fell due to a decrease in legal expenses

REDUCED EQUITY INVESTMENT LOSS - Non-cash loss from equity method investment in Gannet BioChem declined yr/yr

Company press release: ID:nPn5dR7Nga

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Sales
$10.86 mln
Q1 EPS
-$1.82
Q1 Net Income
-$44.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nektar Therapeutics is $150.00, about 76.3% above its May 6 closing price of $85.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)